Toronto, ONTARIO9 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Toronto, ONTARIO

Find 9 actively recruiting myalgic encephalomyelitis clinical trials in Toronto, ONTARIO. Connect with local research sites and explore new treatment options.

9
Active Trials
8
Sponsors
1,662
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Toronto

RecruitingToronto, ONTARIONCT07169578

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to...

800 participants
Hoffmann-La Roche
View Study Details
RecruitingToronto, ONTARIONCT03947385

Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations o...

341 participants
IDEAYA Biosciences
View Study Details
RecruitingToronto, ONTARIONCT03955445

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glo...

225 participants
Novartis Pharmaceuticals
View Study Details
RecruitingToronto, ONTARIONCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in...

81 participants
Laboratoires Thea
View Study Details
RecruitingToronto, ONTARIONCT04899310

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency. The main goal of the study is to assess safe...

63 participants
ModernaTX, Inc.
View Study Details
RecruitingToronto, ONTARIONCT05295433

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT...

63 participants
ModernaTX, Inc.
View Study Details
RecruitingToronto, ONTARIONCT03152058

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid...

55 participants
David Ware Branch
View Study Details
RecruitingToronto, ONTARIONCT04747431

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment ...

25 participants
Passage Bio, Inc.
View Study Details
RecruitingToronto, ONTARIONCT06064890

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations...

9 participants
AviadoBio Ltd
View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Toronto

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 9 myalgic encephalomyelitis clinical trials recruiting participants in Toronto, ONTARIO. These studies are seeking a combined 1,662 participants. Research is being sponsored by Hoffmann-La Roche, IDEAYA Biosciences, Novartis Pharmaceuticals and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Toronto — FAQ

Are there myalgic encephalomyelitis clinical trials in Toronto?

Yes, there are 9 myalgic encephalomyelitis clinical trials currently recruiting in Toronto, ONTARIO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Toronto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Toronto research site will contact you about next steps.

Are clinical trials in Toronto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Toronto studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 9 active trials in Toronto are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov